---
title: "Biotech More Resilient to Tariffs Than Pharma, Medical Tech â€” Market Talk"
date: "2025-02-10 23:47:00"
summary: "Biotechnology is likely to stay resilient despite tariffs, Benchmark analyst Bruce Jackson expects. While development costs may rise, there could be more mergers and acquisitions in the industry if there is less scrutiny from the Federal Trade Commission under the Trump administration. Pharma companies looking to bolster pipelines could also..."
categories:
  - "Dow Jones Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Dow Jones Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Biotechnology is likely to stay resilient despite tariffs, Benchmark analyst Bruce Jackson expects. While development costs may rise, there could be more mergers and acquisitions in the industry if there is less scrutiny from the Federal Trade Commission under the Trump administration. Pharma companies looking to bolster pipelines could also drive merger activity. The metabolic, central nervous system and oncology biotech industries are expected to grow while vaccines and rare diseases are more likely to face challenges. (katherine.hamilton@wsj.com)

[Dow Jones Newswires](https://www.tradingview.com/news/DJN_DN20250210007020:0/)
